ライフサイエンスコーパス: paresthesia

1 be useful as a model stimulus for studies of paresthesia.

2 nderstood conditions such as hyperpathia and paresthesias.

3 OX4 was associated with more neutropenia and paresthesias.

4 ation was commonly associated with transient paresthesias.

5 man presented with blurred vision and distal paresthesias.

6 ofacial paresthesia (4 events [20%]), finger paresthesia (1 event [5%]), and ataxia (1 event [5%]).

7 Some had paresthesias (17%), elevated CSF protein level (13%), an

8 ection (6%), anemia (5%), weakness (6%), and paresthesia (3%).

9 (25% vs. 12%) in the amitriptyline group and paresthesia (31% vs. 8%) and weight loss (8% vs. 0%) in

10 che (46.8%), fatigue (44.2%), malaise (39%), paresthesias (32.5%), peripheral facial palsy (PFP) (36.

11 ted symptoms, most commonly dizziness (59%), paresthesia (34%), euphoria (30%), and hypoesthesia (30%

12 her persistent adverse events were orofacial paresthesia (4 events [20%]), finger paresthesia (1 even

13 opiramate vs placebo, respectively, included paresthesia (50.8% vs 10.6%), taste perversion (23.0% vs

14 upper respiratory tract infection (7%), and paresthesia (7%).

15 ug infusion and included vasodilation (63%), paresthesia (86%), and somnolence (17%).

16 05), and incidences of peripheral neuropathy/paresthesia and alopecia were significantly higher in pa

17 ts may leave soft tissue scarring, and cause paresthesia and lip droop.

18 dose-limiting toxicities, and side effects (paresthesia and rash) were minor.

19 thy in humans that is accompanied by painful paresthesias and dysesthesias.

20 latin neuropathy is characterized by sensory paresthesias and muscle cramps that are notably exacerba

21 hich began with vomiting and upper extremity paresthesias and progressed to fever, seizures, dysphagi

22 Paresthesias and Raynaud's syndrome (hands and feet) sho

23 difficulties, 4 (9%) a sensation of left arm paresthesia, and 3 (7%) sympathetic flight/fright respon

24 norexia, dysgeusia, diarrhea, fatigue, pain, paresthesia, and dyspnea were translated into Italian an

25 arction, leading to upper extremity paresis, paresthesia, and sensory loss.

26 rsity with bilateral leg weakness, ascending paresthesias, and decreased sensation.

27 nausea/vomiting, alopecia, thrombocytopenia, paresthesias, and liver function abnormalities.

28 ble nausea, renal insufficiency, polydipsia, paresthesias, and myelosuppression.

29 r Scale (UNC4P), which rates pain, pruritus, paresthesias, and pliability.

30 erum creatinine level, insomnia, leg cramps, paresthesias, and tremor, were managed with dose reducti

31 Raynaud's phenomenon as persistent pain and paresthesia are common in the hands and arms and occur i

32 Sensory abnormalities such as numbness and paresthesias are often the earliest symptoms in neuroinf

33 lications assessed included axillary seroma, paresthesia, arm morbidity and range of motion, and lymp

34 nausea) and neurological symptoms (extremity paresthesia, arthralgia, myalgia, malaise, pruritus, hea

35 rmation on wound infection, axillary seroma, paresthesia, brachial plexus injury (BPI), and lymphedem

36 ly ash plant family, induces robust tingling paresthesia by activating a subset of somatosensory neur

37 thy in humans that is accompanied by painful paresthesias, dysesthesias, and occasionally hypoesthesi

38 Symptoms included paresthesias, dysesthesias, cold hypersensitivity, jaw p

39 ntinuation in the topiramate groups included paresthesia, fatigue, and nausea.

40 Paresthesias (hands and feet) and tinnitus showed signif

41 Paresthesias have been considered to be an early effect;

42 ons, thereby contributing to radicular pain, paresthesias, hyperalgesia and allodynia.

43 r, and speech abnormalities, with persistent paresthesias in four patients.

44 al anesthesia/analgesia range from transient paresthesias (<10%) to potentially devastating epidural

45 ontinuing topiramate were headache (N=3) and paresthesias (N=2).

46 frequency of blepharoptosis, skin tightness, paresthesias, neck stiffness, muscle weakness, and neck

47 Self-resolving perineal abrasion and focal paresthesia of the glans penis each occurred in one pati

48 fifty-three (76.5%) patients had numbness or paresthesias of the medial arm and/or axilla after surge

49 She did not report paresthesias or blue discoloration of her fingers when t

50 sinophilia, particularly in association with paresthesias or hyperesthesias, should alert clinicians

51 ealed uneventfully without wound dehiscence, paresthesia, or lip droop.

52 (P <or= .0016), seromas (P <or= .0001), and paresthesias (P <or= .0001) than those in the SLND-alone

53 or no diagnostic value, including nocturnal paresthesias; Phalen and Tinel signs; thenar atrophy; an

54 e fatigue, difficulty lifting, and extremity paresthesias) represented strongly clustered symptoms; w

55 tient satisfaction level were discomfort and paresthesia, satisfaction with appearance, and ability t

56 Axillary paresthesia, seroma, and impaired extremity range of mot

57 tallic taste, visual disturbance, circumoral paresthesia, temperature reversal, or toothache) or syst

58 more wound infections, axillary seromas, and paresthesias than SLND alone.

59 and molecular mechanisms underlying tingling paresthesia that accompanies peripheral neuropathy and i

60 The ongoing debate regarding the use of paresthesia versus nerve-stimulator techniques is examin

61 ted in both treatment groups, but tremor and paresthesia were more frequent in the tacrolimus group.

62 ation, neutropenia, febrile neutropenia, and paresthesias were DLTs.

63 rointestinal toxicity, thrombocytopenia, and paresthesias) were all transient.

64 an increased incidence of hypertrichosis and paresthesia, were observed in the patients treated with

65 ) presented with episodic diplopia or facial paresthesias with subsequent brainstem and occasionally

66 latal and pharyngeal reflexes on both sides, paresthesia within the left half of the body.